Orphanet Journal of Rare Diseases
Cure8 research brief
Why This Matters
An oral diabetes drug (empagliflozin) may reduce a toxic metabolite linked to neutropenia and inflammation in GSD Ib, and this case report suggests it helped an adult patient’s blood counts, infections risk, and inflammatory bowel disease–related problems.
Who Should Pay Attention
Adults with GSD Ib, clinicians (metabolic disease specialists, gastroenterologists), and researchers studying metabolic causes of IBD
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
The paper links recent mechanistic work showing accumulation of 1,5-anhydroglucitol-6-phosphate (1,5AG6P) drives neutropenia/neutrophil dysfunction in GSD Ib to use of SGLT2 inhibitors, which reduce renal reabsorption of 1,5-AG.
The reported patient was treated with maximal-dose empagliflozin alongside a structured nutritional plan to maintain physiologic glucose levels. The authors report clinical and laboratory improvement without documented adverse effects and discontinuation of previous supportive measures (nocturnal drip-feeding and respiratory devices).
The report is a single-patient case report, not a clinical trial. Findings may not generalize and do not replace standard medical care; discuss treatment options with specialist clinicians familiar with GSD Ib and SGLT2 inhibitor use.
Keep In Mind
Single-patient case report summarized from the article abstract in Orphanet Journal of Rare Diseases; not a substitute for clinical evidence from controlled studies.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationOrphanet Journal of Rare Diseases
AuthorsClaudio Carallo, Manuela Rosa Spagnolo, Carlo Turi +1 more
InstitutionMagna Graecia University
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedOct 3, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Using GLP-1 Receptor Agonists in Patients with Inflammatory Bowel Disease: A Systematic Review and Single-Arm Meta-Analysis.
People with IBD who need weight loss or have metabolic problems may encounter GLP-1 receptor agonists; this review suggests those drugs reduced weight and improved metabolic measures in people with IBD without clear...
GLP-1 receptor agonists at the crossroads of metabolic and gut inflammation: Implications for people with type 2 diabetes and inflammatory bowel disease.
People with IBD increasingly also have obesity and type 2 diabetes; this commentary suggests GLP-1 receptor agonists might affect not only metabolism but also inflammation and clinical outcomes relevant to IBD, which...
Meta-analysis of the Efficacy and Safety of Ustekinumab in the Treatment of Pediatric Inflammatory Bowel Disease
This pooled analysis focuses on children with IBD and reports that ustekinumab was associated with substantial clinical and steroid-free remission rates and a low incidence of serious adverse events—information that may...